HIV/AIDS News

LIMA, Peru — In a finding described as “reassuring,” researchers detected no interaction between the long-acting HIV prevention drug cabotegravir and hormonal contraceptives among women enrolled in a large trial.

Lima, PERU — Choice, long-lasting protection and HIV prevention in women were three major themes of this week’s HIV Research for Prevention conference.

In adults living with HIV, those with three or more metabolic risk factors had a higher risk for developing new-onset diabetes than those without any risk factors, according to new findings from the REPRIEVE trial.

LIMA, Peru — Positive data continue to roll in for lenacapavir, the long-acting injectable that looks like a game-changer for HIV prevention.

LIMA, Peru — Healio is on site for the International AIDS Society’s HIV Research for Prevention Conference, which will take place from Oct. 6 to 10.

I really enjoyed my residency training at University Hospitals of Cleveland and at the Cleveland VA. Because of some personal issues, I decided that I wanted to join the Public Health Service and work in underserved areas.

Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.

Even before I came to the United States to start my internal medicine residency, I had discovered that my calling was a career in infectious diseases.

HHS this week announced that it will allocate more than $1.4 billion in funding through the Ryan White HIV/AIDS Program to help people with HIV who have low incomes receive medication and care.

In new guidance, the Infectious Diseases Society of America suggested that immunocompromised patients take the monoclonal antibody pemivibart as pre-exposure prophylaxis to prevent severe COVID-19.